How to use the population of TIGIT+ cells as biomarker is very complicated owing to the heterogeneity of autoimmune diseases, disease status, individual differences of patients, etc. Immune checkpoint blockade is showing remarkable efficacy in cancers while it is accompanied by autoimmune disease-like side effects. This evidence concerns the gene TIGIT and autoimmune disease.